Senior Scientist, Advanced Sequencing Applications teams (Hyb & Seq)

NanoString Technologies
Job Location
530 Fairview Ave N
Seattle, WA 98109

See benefits at NanoString

  • NanoString is an EOE
  • NanoString participates in E-Verify. E-Verify is a web-based system that allows an employer to determine an employee's eligibility to work in the US using information reported on an employee's Form I-9. The E-Verify system confirms eligibility with both the Social Security Administration (SSA) and Department of Homeland Security (DHS). For more information, please go to the USCIS E-Verify website.
Job Description

Job Summary:

NanoString is seeking an experienced molecular biologist or biochemist with experience in developing Sequencing Applications.  This position will have a leading role in developing sequencing based applications using Hyb & Seq, a novel single-molecule hybridization-based next generation sequencing (NGS) technology.  They will lead NGS application development by interacting and coordinating with an internal team of highly interdisciplinary technologists whilst also establishing external collaborations.  The successful candidate must be a hands-on experimentalist working  in wet-lab driven research to create innovative application solutions.  Candidates must have strong analytical skills, strong oral and written communication skills, and a track record of developing znc/or utilizing advanced NGS products. Initial Projects will include developing long read sequencing applications and  Immuno-oncology sequencing applications as well as several other key areas. Other responsibilities will include managing external collaborations and external presentations utilizing the unique features of Hyb and Seq technology

Essential Duties:

  • Identify new applications, assist in product development working closely with business analyst and strategic marketing specialists
  • Discover and prioritize potential collaboration opportunities by actively prospecting, collaborating with cross-functional partners and leveraging your network.
  • Apply advanced and expert scientific and product knowledge to NGS application development
  • Establish complete application workflow, sample preparation, sequencing conditions and post run analyses
  • Collaborate with analysts and programmers to develop analysis solutions.
  • Understand the needs and future demands of Clinical Sequencing Customers


  • Ph.D. in Life Sciences with 7+ years of combined industry and post-doctoral work experience in NGS, with significant portion dedicated to applying NGS to customers challenges
  • Demonstrated ability to initiate and carry projects through to conclusion
  • Extensive hands-on, state-of-the-art molecular biology experience
  • Knowledge of nucleic acid characterization techniques, especially hybridization-based assays
  • Experience working with clinically relevant sample types such as FFPE, whole blood and plasma
  • Experience in cancer genomics (knowledge of oncogenic pathways) and/or infectious disease genomics
  • Experience in navigating and extracting information from publicly available databases (NCBI, UCSC, Ensembl, COSMIC, etc.)
  • Experience analyzing and interpreting NGS data from tumor and/or liquid biopsy samples
  • Experience managing customer collaborations
About Our Organization

NanoString Technologies is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

An analysis appearing in PeerJ finds that social media mentions of a paper may lead to increased citations.

NIH's Michael Lauer looks at the number of grants, their amount, and funding success rates at the agency for last year.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.